A Randomized, Double-Blind Phase 3 Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine Plus Placebo For The First-Line Treatment Of Patients With Locally Advanced, Unresectable Or Metastatic Pancreatic Cancer.
A Randomized, Double-Blind Phase 3 Study Of Gemcitabine Plus AG-013736 Versus Gemcitabine Plus Placebo For The First-Line Treatment Of Patients With Locally Advanced, Unresectable Or Metastatic Pancreatic Cancer.
The purpose of this study is to determine whether investigational study drug, AG-013736, and gemcitabine are effective in the first-line treatment of advanced pancreatic cancer.
This study was prematurely discontinued for futility on 23 January 2009, based on a planned interim analysis by an independent Data Safety Monitoring Board (DSMB) that found no evidence of improvement in the primary endpoint (survival) in patients treated with axitinib and gemcitabine compared to gemcitabine alone. Enrollment on this study has been discontinued.
Inclusion Criteria:
Exclusion Criteria:
LaVerne, California 91750, United States
Pleasent Hill, California 94523, United States
East Bentleigh, Victoria 3165, Australia
Kashiwa-shi, Chiba, Japan
Suntougun, Shizuoka, Japan
Chuo-ku, Tokyo, Japan
Kuei-Shan Jsoamg, Taoyuan County 333, Taiwan
Southhampton, S016 6YD, United Kingdom